Get the Stockscreener App
0.9773
1.03%
0.0026
Jaguar Health Inc stock is traded at $0.9773, with a volume of 45,805.
It is up +1.03% in the last 24 hours and down -16.10% over the past month.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
See More
Previous Close:
$0.9799
Open:
$0.9742
24h Volume:
45,805
Relative Volume:
0.17
Market Cap:
$8.78M
Revenue:
$10.72M
Net Income/Loss:
$-39.71M
P/E Ratio:
-0.0628
EPS:
-15.5542
Net Cash Flow:
$-32.21M
1W Performance:
-4.81%
1M Performance:
-16.10%
6M Performance:
-88.43%
1Y Performance:
-95.25%
1-Day Range:
$0.96
$0.9993
1-Week Range:
$0.92
$1.06
52-Week Range:
$0.90
$24.30
Jaguar Health Inc Stock (JAGX) Company Profile
Name
Jaguar Health Inc
Sector
Industry
Phone
415-371-8300
Address
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
Compare JAGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| JAGX | 0.9773 | 8.78M | 10.72M | -39.71M | -32.21M | -15.55 |
| VRTX | 448.26 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 745.57 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 588.39 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.72 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.24 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Jaguar Health Inc Stock (JAGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-17 | Initiated | Rodman & Renshaw | Buy |
Jaguar Health Inc Stock (JAGX) Latest News
Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the YearEurope” - AccessWire
Napo Therapeutics Wins 'Best Pharma Innovator' Award, Advances Rare Disease Drug Trials | JAGX Stock News - StockTitan
Earnings call: Jaguar Health reports revenue growth in Q3 2024 By Investing.com - Investing.com Nigeria
Earnings call: Jaguar Health reports revenue growth in Q3 2024 - Investing.com
Jaguar Health, Inc. (NASDAQ:JAGX) Q3 2024 Earnings Call Transcript - Insider Monkey
Jaguar Health Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Simply Wall St
Jaguar Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Jaguar Health extends agreement with financial managers - Investing.com India
Jaguar Health Inc (JAGX) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... - Yahoo Finance
Jaguar Health Sees Revenue Growth with New Product Launches - TipRanks
Jaguar Health extends agreement with financial managers By Investing.com - Investing.com UK
Jaguar Health reports Q3 EPS ($1.05) vs. ($22.50) last year - TipRanks
Jaguar Health Reports Third Quarter 2024 Financial Results - Yahoo Finance
Jaguar Health to Hold Investor Webcast Wednesday, November 13th at 8:30 AM Eastern Regarding Q3 2024 Financials & Corporate Updates - Bluefield Daily Telegraph
Jaguar Health (JAGX) Sets Q3 2024 Earnings Call: Key Financial Updates Coming | JAGX Stock News - StockTitan
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 27% - Simply Wall St
Jaguar Health stock hits 52-week low at $0.93 amid challenges By Investing.com - Investing.com South Africa
Jaguar Health stock hits 52-week low at $0.93 amid challenges - Investing.com India
JAGXJaguar Health, Inc. Latest Stock News & Market Updates - StockTitan
FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs - Corsicana Daily Sun
Jaguar Health Secures FDA Renewal for Breakthrough Canine Cancer Drug Through 2025 | JAGX Stock News - StockTitan
Jaguar Health announces FDA approval of renewal of Canalevia-CA1 - TipRanks
Abstract Describing Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients Accepted for Presentation at San Antonio Breast Cancer Symposium (SABCS) - StockTitan
JAGX (Jaguar Health) Total Inventories : $9.56 Mil (As of Jun. 2024) - GuruFocus.com
Jaguar Health reports promising crofelemer study results - Investing.com
Jaguar Health reports promising crofelemer study results By Investing.com - Investing.com UK
Significant Positive Results with Jaguar Health's Crofelemer for Chronic Refractory Diarrhea in IBS-D, Presented at American College of Gastroenterology Annual MeetingChannel3000.com - Channel3000.com - WISC-TV3
Small-cap biotech Jaguar Health’s stock jumps as it launches treatment for a painful side effect of cancer treatment - MSN
Jaguar Health Launches FDA-Approved Oral Mucositis Prescription Product Gelclair in the U.S. - BioSpace
Small-cap biotech Jaguar Health’s stock jumps 7% as it launches treatment for oral mucositis in cancer patients - MSN
Jaguar Health launches Gelclair for oral mucositis relief By Investing.com - Investing.com South Africa
Jaguar Health’s stock jumps as it launches treatment for oral mucositis - MarketWatch
Jaguar Health launches Gelclair for oral mucositis relief - Investing.com
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - guardonline.com
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present October 16 at BIO Investor Forum - Corsicana Daily Sun
Jaguar Health Inc (JAGX) Q2 2024 Earnings Call Highlights: Revenue Growth Amidst Financial ... - Yahoo Finance
Jaguar Health Inc (JAGX) Q2 2024 Earnings Call Highlights: Revenue Growth Amidst Financial ... By GuruFocus - Investing.com Canada
Jaguar Health Submits Abstract for First-of-Kind Study Evaluating the Impact of Diarrhea from Cancer Therapies in Breast Cancer Patients Who Received Placebo in its OnTarget Phase 3 Trial - Joplin Globe
Jaguar’s diarrhoea drug shows benefit in Phase III breast cancer subgroup - Clinical Trials Arena
Jaguar Health Reports Statistically Significant Improvement in Breast Cancer Patients in its Phase 3 OnTarget Trial for its Cancer Supportive Care Drug Crofelemer - Corsicana Daily Sun
Jaguar Health Scientific Advisory Board Member to Share Poster Presentation at American Society of Clinical Oncology (ASCO) Quality Care Symposium About the Methodologies Involved in Designing an Advocate-Led Quality of Life Survey for Cancer Patien - AccessWire
Jaguar Health to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024 - StockTitan
Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care at American Society for Radiation Oncology (ASTRO) Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024 Gelclair Launch - BioSpace
Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care at American Society for Radiation Oncology (ASTRO) Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in... - Markets Insider
Jaguar Health Inc Stock (JAGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):